San Diego, CA -- (SBWIRE) -- 06/01/2015 -- An investor, who purchased shares of IsoRay, Inc. (NYSEMKT:ISR), filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by IsoRay, Inc. in connection with certain allegedly false and misleading statements made between May 20, 2015 and May 21, 2015.

Investors who purchased shares of IsoRay, Inc. (NYSEMKT:ISR) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2015. NYSEMKT:ISR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of IsoRay, Inc. (NYSEMKT:ISR) common shares between May 20, 2015 and May 21, 2015, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that Defendants allegedly made false and/or misleading statements regarding IsoRay's Celsium-131 isotope seeds and mesh for the treatment of non-small cell lung cancers and that when the true details entered the market, shares of IsoRay, Inc. (NYSEMKT:ISR) fell $1.10 per share or over 35% to close at $2.02 per share on May 21, 2015, damaging investors.

IsoRay, Inc. reported that its Total Revenue declined from $5.24 million for the 12 months period that ended on June 30, 2011 to $4.22 million for the 12 months period that ended on June 30, 2014 and that its Net loss for those respective time periods increased from $2.84 million to $5.96 million.

On May 20, 2015, IsoRay, Inc. announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer.

Shares of IsoRay, Inc. (NYSEMKT:ISR) grew from $1.48 per sahare on May 19, 2015, to as high as $3.79 per share on May 21, 2015.

However, on May 21, 2015, an article was published that said that "IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy" and "to make up for the inability to deliver revenue growth -- and prop up its stock price"

Shares of IsoRay, Inc. (NYSEMKT:ISR) closed on May 28, 2015 at $1.92 per share.

Those who purchased shares of IsoRay, Inc. (NYSEMKT:ISR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com